Research Development Foundation

The University of Texas System

Research Development Corporation

Bryant G Darnay

Bharat B Aggarwal

Moshe Talpaz

Sujay Singh

Janet E Price

Ann Poblenz

The present invention include methods and compositions for treating bone-resorbing diseases or bone resorption related to a pathologic condition generally, including, but not limited to osteoporosis, arthritis, rheumatoid arthritis, cancer metastases to the bone, bone cancer, hypercalcemia, osteolytic lesions with orthopedic implants, Paget's disease, and bone loss associated with hyperparathyroidism. Representative cancers include, but are not limited to breast cancer, prostrate cancer, colon cancer, endometrial cancer, multiple myeloma, renal cell carcinoma, heck and neck cancers, and cervical carcinoma. Arthritic conditions include, but are not limited to adjuvant-, collagen-, bacterial- and antigen-induced arthritis, particularly rheumatoid arthritis.

Inhibition of osteolytic lesions by SRC kinase inhibitors

The present invention provides a RANK (receptor activator of NF-&#x3ba;B) inhibitor consisted of a TRAF-6 (TNF receptor-associated factor-6) binding domain attached to a leader sequence. The peptide inhibitor inhibits RANKL (RANK ligand)-mediated osteoclast differentiation, thus indicating that targeted disruption of interaction between RANK and TRAF6 may prove useful as a therapeutic for metabolic bone disorders, leukemia, arthritis, and metastatic cancer of the bone.

Inhibitors of receptor activator of NF-&#x3ba;B and uses thereof

The present invention provides an isolated and purified protein that associates with the cytoplasmic domain of the p60 form of the tumor necrosis factor receptor, having a molecular weight of about 52-55 kDa on SDS-PAGE, is a phosphoprotein, and does not bind to the p80 form of the tumor necrosis factor receptor. Also provided is an isolated and purified protein kinase that binds to the cytoplasmic domain of the p60 form of the tumor necrosis factor receptor, said kinase phosphorylates the p60 form of the tumor necrosis factor receptor. Also provided are various methods of manipulating this tumor necrosis factor receptor-associated protein and kinase in order to reduce various biological effects of tumor necrosis factor.

Tumor necrosis factor receptor-I-associated protein kinase and methods

The present invention provides an isolated and purified protein that associates with the cytoplasmic domain of the p80 form of the tumor necrosis factor receptor, having a molecular weight of 59 kDa on SDS-PAGE, is a phosphoprotein, and does not bind to the p60 form of the tumor necrosis factor receptor. Also provided is an isolated and purified protein kinase that associates with the cytoplasmic domain of the p80 form of the tumor necrosis factor receptor, said kinase phosphorylates both the p80 and p60 forms of the tumor necrosis factor receptor and phosphorylates a 59 kDa molecular weight protein associated with the cytoplasmic domain of the p80 form of the tumor necrosis factor receptor. Also provided are various methods of reducing the biological effects of tumor necrosis factor.

Growing community of inventors

Houston, TX, United States of America

Bryant G Darnay